A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

These healthcare stocks have long-term and profitable growth runways.

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been ...

DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.

What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...

The S&P 500 SPX has risen 14.5% this year through Friday. All price changes in this article exclude dividends. Through Friday, 57% of stocks in the S&P 500 were up for 2025.

The average one-year price target for DexCom (NasdaqGS:DXCM) has been revised to $88.30 / share. This is a decrease of 13.54% ...

DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...